



**ASX ANNOUNCEMENT**

**10 March 2017**

## **Proactive Investor Conference Presentation**

Please find enclosed an Investor Presentation, which Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), will be presenting at the *Proactive's CEO Spotlight Investor Session*.

Cynata Managing Director and Chief Executive Officer Dr Ross Macdonald will be presenting at the event in Sydney and Melbourne on the following dates.

**Sydney – Tuesday, 14<sup>th</sup> March 2017 from 12-noon to 2.30pm**

Radisson Blu Hotel, Marble Room (Cnr. Pitt and O'Connell Street, Sydney)

**Melbourne – Wednesday, 15<sup>th</sup> March 2017 from 12-noon to 2.30pm**

CQ Functions, Events Room 1 (113 Queen Street, Melbourne)

**For more information and to register your interest in attending please go to:**

<http://www.proactiveinvestors.com.au/events>

The Presentation will focus on the Company's leading Cymerus™ technology that utilises induced pluripotent stem cells (iPSCs) from just one donor in a one-time donation to produce and manufacture mesenchymal stem cells (MSCs) for therapeutic use. The presentation will cover the benefits of this technology, the medical conditions that it seeks to address and the significant market opportunity.

The Company will also discuss its strategic alliance with FUJIFILM, a global leader in regenerative medicine, to develop and commercialise Cynata's technology, including its first Cymerus MSC product, CYP-001 which is poised to begin a world-first clinical trial.

**Ends**

**CONTACTS:** Dr Ross Macdonald, CEO: Tel: 0412 119343; email [ross.macdonald@cynata.com](mailto:ross.macdonald@cynata.com)  
Andrew Ramadge, Australia Media Contact, 0475 797 471, [andrew.ramadge@mcpartners.com.au](mailto:andrew.ramadge@mcpartners.com.au)